Catalog No.
Product Name
Application
Product Information
Citations
-
Tubulin Inhibitor
Tubulin Inhibitor 22 is a potent inhibitor of tubulin, demonstrating significant anti-angiogenic and anti-cancer properties. It effectively arrests the MGC-803 cell cycle at the G2/M phase, leading to a dose-dependent induction of Caspase-mediated apoptosis through mitochondrial dysfunction. This compound is valuable for research applications in cancer biology and the study of cell cycle regulation. -
Tubulin Inhibitor
ABI-274 is a potent tubulin inhibitor that targets the colchicine binding site. This compound significantly enhances cancer cell apoptosis in vitro when used in combination with vemurafenib, exhibiting strong synergistic effects. In vivo studies demonstrate its efficacy in vemurafenib-resistant xenograft models in nude mice, making ABI-274 a critical tool for research on melanoma and potential therapeutic strategies in resistant cancer forms. -
Drug Isomer
(R)-Taltobulin, also known as (R)-HTI-286, serves as a reference isomer utilized in drug development research. This compound is primarily studied for its effects on tubulin polymerization, which plays a critical role in cell division and cancer progression. Its applications include evaluating the pharmacological properties of microtubule-targeting agents and advancing cancer therapeutics. -
Anti-microtubular Agent
Deacetoxyvinzolidine is a bis-indole derivative that functions as an anti-microtubular agent by disrupting microtubule assembly. It demonstrates a strong affinity for bovine purified brain tubulin, with a Kd of 3 μM, effectively inhibiting microtubule formation at concentrations as low as 10 nM. Its significant anti-tumoral properties make it a valuable tool for research, particularly in the investigation of leukemia and related malignancies. -
Negative Control
Microtubule Destabilizing Agent-3 (negative control) is a reagent designed to serve as a negative control in studies investigating microtubule dynamics. While genuine microtubule destabilizing agents induce disruptions in the microtubule network and promote mitotic arrest, this negative control allows for the assessment of assay specificity. It is crucial for evaluating the role of microtubule destabilization in various cellular processes, including apoptosis and cell cycle regulation, without exerting direct biological effects. -
Antitumor Compound
Vinzolidine is a semisynthetic derivative of catharanthus alkaloids that targets microtubulin polymerization to exert cytotoxic effects on tumor cells, inhibiting cell division. This antitumor compound is valuable in research for investigating synergistic effects with other chemotherapeutic agents or biologic therapies, as well as studying the tolerance and resistance of cancer cells to these treatments. Vinzolidine serves as a useful tool for exploring new strategies to overcome therapeutic challenges in cancer research. -
Anticancer Agent
Anticancer agent 60, also known as compound 3h, primarily targets cancer cell proliferation. It exhibits significant antiproliferative activity against human HepG2 cells, with an IC50 value of 4.13 μM. Additionally, this compound demonstrates antitumor efficacy in a human HepG2 xenograft mouse model, making it a valuable tool for cancer research and therapeutic development. -
Tubulin Inhibitor
Tubulin inhibitor 8 (Compound 33b) is a potent inhibitor of tubulin polymerization, demonstrating an IC50 value of 0.73 μM. This compound effectively inhibits the growth of K562 cancer cells, achieving an IC50 of 14 nM. Tubulin inhibitor 8 is valuable for studies in cancer research, particularly in evaluating mechanisms of action related to cytoskeletal dynamics and potential therapeutic interventions in tumor proliferation. -
Tubulin Inhibitor
Tubulin Inhibitor 7 is a potent inhibitor of tubulin polymerization, targeting microtubule dynamics critical for cell division. With an IC50 of 0.52 μM, it effectively disrupts tubulin assembly, exhibiting significant anti-proliferative activity in various cancer cell lines. Notably, Tubulin Inhibitor 7 demonstrates an IC50 of 11 nM against K562 cells, making it a valuable tool for cancer research and studies focused on mitotic disruption. -
Tubulin Inhibitor
Tubulin Inhibitor 29 is a potent inhibitor of tubulin assembly, exhibiting an IC50 value of 1.2 µM. This compound demonstrates significant antiproliferative activity, with an IC50 value of 7.5 µM against MCF-7 breast cancer cells. By binding to the colchicine site on tubulin, Tubulin Inhibitor 29 disrupts microtubule dynamics, making it a valuable tool for cancer research and studies focused on cell cycle regulation. -
Microtubule Inhibitor
Cevipabulin fumarate dihydrate is a potent microtubule inhibitor targeting tubulin to disrupt microtubule dynamics. This orally administered antitumor compound demonstrates significant cytotoxic activity in human tumor cell lines, with an IC50 range of 18-40 nM. Cevipabulin is primarily used in cancer research to explore mechanisms of tumor cell proliferation and resistance, providing valuable insights for therapeutic development. -
Tubulin Polymerization Inhibitor
Tubulin polymerization-IN-63 is a potent inhibitor of tubulin polymerization, demonstrating an IC50 value of 0.29 μM in MES-SA cells. This compound disrupts microtubule dynamics, making it a valuable tool for cancer research. It aids in the exploration of cellular responses to tubulin modulation and contributes to the understanding of tumor biology and therapeutic strategies. -
Tubulin Inhibitor
Tubulin Inhibitor 26 is a potent indazole derivative targeting tubulin. It exhibits low nanomolar potency against various cancer cell lines, including HepG2, HCT116, SW620, HT29, and A549. This compound effectively induces G2/M phase arrest and promotes apoptosis in tumor cells. Furthermore, Tubulin Inhibitor 26 demonstrates the ability to suppress tumor growth in vivo while maintaining normal body weight in mice. -
Tubulin/FTase Inhibitor
Tubulin polymerization-IN-25 is a dual inhibitor targeting tubulin polymerization and farnesyl transferase (FTase), exhibiting IC50 values of 1.11 μM and 0.39 μM, respectively. This compound demonstrates significant cytotoxicity and potent antitumor activity, making it a valuable tool for cancer research. Its ability to disrupt microtubule dynamics and inhibit protein farnesylation underscores its potential in therapeutic applications focused on tumor growth suppression. -
Microtubule Synthesis Inhibitor
Antitumor agent-200 is a microtubule synthesis inhibitor that targets the colchicine site on tubulin, leading to G2/M cell cycle arrest and the generation of reactive oxygen species (ROS). This compound demonstrates significant inhibitory activity against MCF7/ADR and KBV200 cell lines exhibiting P-glycoprotein overexpression, with drug resistance indices of 0.83 and 0.58, respectively. In vivo studies using the MCF-7 xenograft model have shown that Antitumor agent-200 at a dosage of 25 mg/kg via intraperitoneal injection results in a tumor growth inhibition rate of 57.2%. This reagent is valuable for research in the oncology field, particularly in studies related to drug resistance and cancer treatment efficacy. -
Tubulin Polymerization Inhibitor
Tubulin polymerization-IN-87 is a potent inhibitor of tubulin polymerization. This compound disrupts the assembly of microtubules, resulting in G2/M cell cycle arrest and exhibiting significant anti-proliferative effects. It is particularly effective against ovarian cancer, providing valuable insights for research applications in cancer biology and therapeutic development. -
Utrophin Modulator
OX01914 is a water-soluble utrophin modulator that enhances utrophin protein levels, demonstrating an EC50 value of 20.5 μM. This compound serves as a valuable tool in the study of Duchenne muscular dystrophy (DMD), facilitating research aimed at developing therapeutic strategies for this condition. Its mechanism of action supports investigations into muscle regeneration and the functional recovery of dystrophic muscle tissue. -
Tubulin Polymerization Inhibitor
Tubulin polymerization-IN-10 is a potent inhibitor of tubulin polymerization, exhibiting an IC50 of 4.25±0.75 μM. This compound demonstrates significant anti-tumor activity, making it a valuable tool for cancer research and studies focusing on microtubule dynamics. Its ability to disrupt tubulin assembly can be leveraged in the investigation of various cancer therapies. -
Microtubule Depolymerizer
Phomopsin B, a hexapeptide derived from the fungus Phomopsis leptostromiformis, functions as a microtubule depolymerizer. This compound exhibits significant antimitotic activity, making it a valuable tool in cancer research. Its ability to disrupt microtubule dynamics renders it useful for studying cellular processes in tumor biology and investigating potential therapeutic strategies against cancer. -
Utrophin Modulator
Utrophin modulator 1 is a potent utrophin modulator that upregulates utrophin protein levels, demonstrating an EC50 value of 0.11 μM. This compound is particularly relevant in research focused on Duchenne muscular dystrophy (DMD), offering a valuable tool for studies aimed at exploring therapeutic strategies for this debilitating condition. Its ability to enhance utrophin expression positions it as a promising candidate in the development of targeted treatments. -
Tubulin Polymerization Inhibitor
Tubulin polymerization-IN-37 is an effective tubulin polymerization inhibitor, exhibiting an IC50 value of 2.3 μM. By binding to the colchicine site on tubulin, it disrupts the normal polymerization process and inhibits colchicine binding. This compound is valuable in cancer research, particularly in studying various lymphomas and their underlying mechanisms. -
Microtubule/Tubulin Modulator
Fosbretabulin tromethamine is a tubulin modulator that disrupts microtubule dynamics. It acts as a vascular disrupting agent, primarily targeted for the treatment of anaplastic thyroid carcinoma (ATC) by inducing acute, reversible reductions in tumor blood flow and resulting in central necrosis. This compound is instrumental in researching tumor vasculature and assessing therapeutic strategies aimed at disrupting blood supply to tumors. -
Tubulin inhibitor
Tubulin Inhibitor 15 is a potent compound that disrupts microtubule dynamics by binding to tubulin. This reagent demonstrates significant antiproliferative activity, exhibiting cytotoxic effects specifically in HepG2 liver cancer cells. It is a valuable tool for research focused on cancer biology and the mechanisms of cell division and proliferation. -
Tubulin Inhibitor
BNZ-111 is an orally bioavailable inhibitor of tubulin, targeting microtubule dynamics. This compound exhibits significant antitumor activity, making it a valuable tool for cancer research. BNZ-111 can be utilized in studies focused on the mechanistic understanding of microtubule-targeting therapies and their potential clinical applications in oncology. -
Polymerization Inhibitor Prodrug
Tubulin Polymerization-IN-1 prodrug is a palladium-mediated inhibitor of tubulin polymerization, developed to target the colchicine binding site. This prodrug demonstrates significantly reduced cytotoxicity compared to its parent compound, offering a 68.3-fold reduction in toxicity while maintaining effectiveness upon activation by Pd resin. Mechanistic investigations align its anticancer activity with that of colchicine binding site inhibitors. In vivo studies have shown that treatment with Tubulin Polymerization-IN-1 prodrug results in a substantial inhibition of tumor growth (63.2%) following Pd resin activation. This compound holds potential for advancing research in anticancer therapeutics. -
Tubulin Inhibitor
Tubulin Inhibitor 44 is a potent inhibitor targeting tubulin, disrupting its function in microtubule dynamics. This compound exhibits significant cytotoxicity in cancer cell lines such as NCI-H460, BxPC-3, and HT-29, with IC50 values of 0.96 nM, 0.66 nM, and 0.61 nM, respectively. Its efficacy makes it a valuable tool for research in cancer biology and drug discovery focused on microtubule-targeting agents. -
Tubulin Inhibitor
Ohchinolide B is a potent tubulin inhibitor that effectively disrupts microtubule polymerization with an IC50 of 2.3 μM. This compound induces G2/M phase cell cycle arrest and activates mitochondrial apoptotic pathways, making it a valuable tool for studying cancer biology. Ohchinolide B is particularly promising for research involving solid tumors, including breast and lung cancer. -
Tubulin Inhibitor
3,3'-Dihydroxy-2,6-bis(4-hydroxybenzyl)-5-methoxybibenzyl is a potent tubulin inhibitor with an IC50 of 10 μM, effectively inhibiting tubulin polymerization. This stilbenoid compound enhances the cytotoxic effects of SN-38 in BCRP-transduced cancer cells, making it a valuable tool for cancer research. Its application is particularly relevant in the study of breast cancer, where it can help elucidate mechanisms of drug resistance and potential therapeutic strategies. -
Microtubule Inhibitor
Isodienestrol is a microtubule inhibitor that disrupts the normal function of the cytoskeletal structure. This compound is primarily utilized in cancer research, where it demonstrates potential effectiveness in inhibiting tumor cell proliferation and inducing apoptosis. Its mechanism of action makes it a valuable tool for investigating microtubule dynamics and their role in oncogenic processes. -
Tubulin Inhibitor
Tubulin Inhibitor 12 is a selective antagonist of tubulin with an IC50 value of 25.3 μM. This compound exhibits significant anti-tumor and anti-proliferative activities, making it a valuable tool for cancer research. It is ideally suited for studies focused on cell cycle regulation and mechanisms of tumor growth inhibition. -
Microtubule Assembly Inhibitor
Myoseverin B is a microtubule assembly inhibitor that effectively disrupts tubulin polymerization with an IC50 of 2 μM. This compound demonstrates low cytotoxicity across various cell types, making it a valuable tool in cellular studies. Myoseverin B is primarily utilized in research focused on antitumor mechanisms and the exploration of microtubule dynamics in cancer biology. -
Tubulin polymerization Inhibitor
Tubulin polymerization-IN-29 is a potent inhibitor of tubulin polymerization, effectively disrupting microtubule dynamics. This compound demonstrates significant antiproliferative activity and is capable of inducing cell cycle arrest in HeLa cells at the G2/M phase. It serves as a valuable tool for research involving cancer biology and cell proliferation studies. -
Tubulin Polymerization Inhibitor
Tubulin Polymerization-IN-52 is a selective inhibitor of tubulin polymerization, demonstrating an IC50 of 2.9 μM. This compound disrupts microtubule dynamics, making it a valuable tool for studying cytoskeletal function and cell division. Its inhibitory effects on tubulin polymerization can be leveraged in cancer research and investigations into related disorders. -
Angiogenesis inhibitors
Denibulin hydrochloride is an anti-angiogenic agent that targets and disrupts the formation of blood vessels in solid tumors. This compound demonstrates significant anticancer activity by promoting rapid closure of tumor-associated vasculature, which can lead to a dose-dependent reduction in tumor cell viability. Denibulin hydrochloride enhances the efficacy of radiation and cisplatin chemotherapy, making it a valuable tool for research in cancer therapeutics and vasculature dynamics. -
Tubulin Polymerization Inhibitor
Tubulin polymerization-IN-55 is a potent inhibitor of tubulin polymerization, disrupting microtubule dynamics. This reagent exhibits significant antiproliferative activity against various cancer cell lines, including A549, K562, HepG2, MDA-MB-231, and HFL-1, with IC50 values of 8, 3, 9, 24, and 62 nM, respectively. It serves as a valuable tool for researchers studying cancer biology and cellular mechanisms involving microtubules. -
Tubulin Polymerization/Akt Pathway Inhibitor
KS-99 is an inhibitor that targets both tubulin polymerization and the Akt signaling pathway. This compound demonstrates significant biological activity by inhibiting cancer cell proliferation and inducing apoptosis in various cancer cell types. KS-99 is suitable for research applications involving colorectal cancer, breast cancer, lung epithelial cancer, and melanoma. -
Microtubule Inhibitor
Taxinine B is a microtubule inhibitor derived from the Japanese Yew (Taxus cuspidata). It effectively inhibits CaCl2-induced depolymerization of microtubules, contributing to its potential in cancer research. Taxinine B may also be valuable for overcoming multidrug resistance in tumor cells, making it a significant compound for studies focused on cancer treatment and cellular mechanisms. -
Antitumor Agent
Antitumor Agent-71 is an antitumor agent that inhibits tubulin polymerization, thereby disrupting microtubule dynamics essential for cell division. It exhibits significant antiproliferative activity against various tumor cell lines, with IC50 values between 3.98 and 15.70 μM. This compound is valuable for research applications focused on cancer biology and the development of novel chemotherapeutic strategies. -
Tubulin Polymerization Inhibitor
Tubulin polymerization-IN-77 is a potent inhibitor of tubulin polymerization, specifically targeting the microtubule dynamics crucial for cell division. This compound exhibits notable anti-glioblastoma activity by inducing G2/M phase arrest and promoting apoptosis in glioblastoma cells. Additionally, Tubulin polymerization-IN-77 is characterized by significant permeability across the blood-brain barrier and effectively reduces tumor cell migration, making it a valuable reagent for cancer research applications focused on glioblastoma therapeutics. -
Microtubule Inhibitor
JC168 is a phenyl analog of peloruside that acts as a microtubule inhibitor. It exhibits significant antiproliferative and anticancer activities by promoting tubulin polymerization, thus disrupting microtubule dynamics. This compound is valuable for research on microtubule-associated disorders and offers potential insights into cancer biology. -
Microtubule Inhibitor
Anticancer agent 98 is a microtubule inhibitor that disrupts tubulin polymerization with a Kd of 16.9 μM. This compound demonstrates significant antiproliferative activity against various tumor cell lines and exhibits an anti-angiogenic effect in vitro. Additionally, Anticancer agent 98 shows favorable stability in human and mouse liver microsomes, with a half-life greater than 300 minutes, making it a valuable candidate for further research in cancer therapeutics. -
Tubulin Inhibitor
ALB-109564 hydrochloride, a tubulin inhibitor, effectively disrupts mitosis in cancer cells, leading to cytotoxicity. This compound is utilized in research focused on cancer biology and treatment strategies, particularly in studies examining the mechanisms of cell division and potential therapeutic interventions for tumor growth. Its ability to impair microtubule dynamics makes it a valuable tool for investigating novel anti-cancer modalities. -
Microtubule/Tubulin
Microtubule Inhibitor 3 targets tubulin, disrupting microtubule dynamics and resulting in cytotoxic activity against diverse human cancer cell lines. With an IC50 value of 14.0 nM in NCI-H460 cells, this compound, along with its analogs, demonstrates potent efficacy in inhibiting cell proliferation. Its applications extend to cancer research, particularly in studying microtubule-targeted therapies. -
Tubulin Inhibitor
Neuroinflammatory-IN-3 is a tubulin inhibitor that exhibits anti-neuroinflammatory properties. It acts by preventing tubulin polymerization, which disrupts microtubule dynamics. This compound has demonstrated potential as an effective antitumor agent, making it valuable for research in cancer biology and neuroinflammatory diseases. -
Tubulin Polymerization Inhibitor
Tubulin polymerization-IN-8 is a potent inhibitor of tubulin polymerization, primarily targeting microtubule dynamics. It effectively induces G2/M phase cell cycle arrest in HCT116 tumor cells, demonstrating a significant inhibitory potency with an IC50 value of 12.7 μM. This compound is valuable for research applications in cancer biology, particularly in studies focused on tumor cell proliferation and microtubule-targeting therapies. -
Tubulin Polymerization Inhibitor
Tubulin polymerization-IN-20 is a potent inhibitor of tubulin polymerization, targeting the assembly of microtubules crucial for cell division. This compound exhibits significant potential in the study of breast cancers and chemoresistant colon cancers, facilitating research into mechanisms of resistance and offering insights for therapeutic strategies. Its effectiveness in disrupting microtubule dynamics makes it a valuable tool for cancer research applications. -
Melanoma Inhibitor
Anti-melanoma agent 3 is a 2-aryl-4-benzoyl-imidazole (ABI) derivative designed to inhibit melanoma xenografts. This compound demonstrates significant anticancer activity by targeting the colchicine binding site, leading to the inhibition of tubulin polymerization. It is particularly useful in research focused on developing effective treatments for melanoma by disrupting cellular mitosis and tumor growth. -
Tubulin Inhibitor
Tubulin Inhibitor 20 is a potent inhibitor of tubulin, disrupting microtubule dynamics and thereby affecting cellular processes such as mitosis and intracellular transport. This compound demonstrates significant anti-cancer activity, making it a valuable tool for research into cancer biology and therapeutic development. Its ability to inhibit tubulin polymerization positions it as a critical reagent for studies aimed at understanding tumor progression and the mechanisms of action of anti-cancer therapies. -
Tubulin Inhibitor
Cemadotin hydrochloride is a potent tubulin inhibitor that disrupts microtubule dynamics, leading to cell cycle arrest in the mitotic phase. With a Ki value of 1 μM, it effectively inhibits cell proliferation in vitro and reduces tumor xenograft growth in murine models. This compound is an important tool for investigating anticancer mechanisms and potential therapeutic applications in cancer research. -
Paclitaxel Derivative
2'-O-TBDMS-Paclitaxel is a derivative of the well-known chemotherapeutic agent Paclitaxel, with the 2'-hydroxyl group protected as a tert-butyldimethylsilyl (TBDMS) ether. This modification enhances the compound's stability and solubility, making it suitable for various chemical biology applications. 2'-O-TBDMS-Paclitaxel serves as a valuable tool in cancer research, particularly in studies focusing on drug delivery systems and the development of novel therapeutics.
